Concord Medical Services Holdings (Concord Medical Services Holdings) 3-Year EBITDA Growth Rate : 5.10% (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Concord Medical Services Holdings 3-Year EBITDA Growth Rate?

Concord Medical Services Holdings's EBITDA per Share for the six months ended in Dec. 2023 was $-0.77.

During the past 3 years, the average EBITDA Per Share Growth Rate was 5.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -18.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Concord Medical Services Holdings was 13.80% per year. The lowest was -67.40% per year. And the median was -20.70% per year.

Competitive Comparison of Concord Medical Services Holdings's 3-Year EBITDA Growth Rate

For the Medical Care Facilities subindustry, Concord Medical Services Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Concord Medical Services Holdings's 3-Year EBITDA Growth Rate Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Concord Medical Services Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Concord Medical Services Holdings's 3-Year EBITDA Growth Rate falls into.

Concord Medical Services Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Concord Medical Services Holdings (NYSE:CCM) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Concord Medical Services Holdings 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Concord Medical Services Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Concord Medical Services Holdings (Concord Medical Services Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Concord Medical Services Holdings Ltd (NYSE:CCM) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Room 2701-05 , 36 North Third Ring Road, Tower A, Global Trade Center, Dongcheng District, Beijing, CHN, 100013

Website

https://ir.ccm.cn

Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company operates cooperative centers across several provinces and administrative regions in China. Its network includes radiotherapy centers and diagnostic imaging centers and centers providing other treatment and diagnostic services, such as electroencephalography for the diagnosis of epilepsy, thermotherapy to increase the efficacy of and for pain relief after radiotherapy and chemotherapy, high intensity focused ultrasound therapy for the treatment of cancer, stereotactic radiofrequency ablation for the treatment of Parkinson's Disease and refraction and tonometry for the diagnosis of ophthalmic conditions.